- Home
- JAZZ vs GDS Comparison
JAZZ vs GDS Comparison
Compare JAZZ & GDS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | JAZZ | GDS |
|---|---|---|
| Founded | 2003 | 2001 |
| Country | Ireland | China |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Programming Data Processing |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.4B | 9.0B |
| IPO Year | 2007 | 2016 |
Fundamental Metrics
Financial Performance| Metric | JAZZ | GDS |
|---|---|---|
| Price | $162.98 | $42.51 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 16 | 9 |
| Target Price | ★ $207.19 | $46.20 |
| AVG Volume (30 Days) | 1.0M | ★ 3.0M |
| Earning Date | 02-24-2026 | 03-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 3.59 |
| Revenue | ★ $4,157,832,999.00 | $1,573,383,809.00 |
| Revenue This Year | $6.05 | $13.03 |
| Revenue Next Year | $6.23 | $12.55 |
| P/E Ratio | ★ N/A | $49.79 |
| Revenue Growth | 4.14 | ★ 11.86 |
| 52 Week Low | $95.49 | $16.93 |
| 52 Week High | $182.99 | $52.50 |
Technical Indicators
Market Signals| Indicator | JAZZ | GDS |
|---|---|---|
| Relative Strength Index (RSI) | 48.53 | 55.48 |
| Support Level | $162.24 | $40.71 |
| Resistance Level | $168.47 | $46.26 |
| Average True Range (ATR) | 4.02 | 2.37 |
| MACD | -0.39 | -0.42 |
| Stochastic Oscillator | 36.31 | 57.47 |
Price Performance
Historical ComparisonAbout JAZZ Jazz Pharmaceuticals plc (Ireland)
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
About GDS GDS Holdings Limited ADS
GDS Holdings started as an IT service provider in 2001 then moved to the data center business with its first self-developed data center opening in 2010. The company now develops and operates data centers in China and also builds, operates and transfers data centers for other clients. It offers colocation and managed services and mainly targets hyperscale cloud service customers who take large areas of its data centers or even whole data centers under long-term contracts. Its data centers are located predominantly in and around the Tier 1 cities in China and it has also started an expanding into Southeast Asia via the now 38% owned DayOne. GDS listed on the Nasdaq in 2016 and completed a secondary listing in Hong Kong in 2020.